AbCellera Biologics (ABCL) Total Liabilities (2020 - 2025)

Historic Total Liabilities for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $392.0 million.

  • AbCellera Biologics' Total Liabilities rose 2453.5% to $392.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.0 million, marking a year-over-year increase of 2453.5%. This contributed to the annual value of $304.5 million for FY2024, which is 932.38% down from last year.
  • Per AbCellera Biologics' latest filing, its Total Liabilities stood at $392.0 million for Q3 2025, which was up 2453.5% from $395.0 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Total Liabilities peaked at $395.0 million during Q2 2025, and registered a low of $171.4 million during Q1 2021.
  • For the 5-year period, AbCellera Biologics' Total Liabilities averaged around $310.6 million, with its median value being $314.7 million (2024).
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 12449.49% in 2022, then crashed by 2478.36% in 2023.
  • Quarter analysis of 5 years shows AbCellera Biologics' Total Liabilities stood at $292.8 million in 2021, then grew by 5.05% to $307.6 million in 2022, then grew by 9.15% to $335.8 million in 2023, then fell by 9.32% to $304.5 million in 2024, then increased by 28.73% to $392.0 million in 2025.
  • Its Total Liabilities was $392.0 million in Q3 2025, compared to $395.0 million in Q2 2025 and $321.2 million in Q1 2025.